Wyniki wyszukiwania

1

Insights into the mechanisms involved in mediating magnesium regulation of tumor growth

100%

Bernardini D., Nasulewicz A., Wolf F., Boninsegna A., Zimowska W., Opolski A., Mazur A., Maier J.

Journal of Elementology

|

2005

|

tom 10

|

nr 4 Suppl.1

18

2

Advances in studies on invasive tumor growth and metastasis

88%

Radzikowski C.

Cellular and Molecular Biology Letters

|

2002

|

tom 07

|

nr Suppl.

3

Alterations in glycosaminoglycan composition of methylcholanthrene - induced sarcoma at various stages of the tumour growth

88%

Wolanska M., Sobolewski K., Bankowski E., Chyczewski L.

Folia Histochemica et Cytobiologica

|

1996

|

tom 34

|

nr 1

4

Ascorbic acid inhibits the migration of Walker 256 carcinosarcoma cells

75%

Wybieralska E., Koza M., Sroka J., Czyz J., Madeja Z.

Cellular and Molecular Biology Letters

|

2008

|

tom 13

|

nr 1

103-111

The results of several experimental studies have shown that ascorbic acid inhibits tumor growth and metastasis. Ascorbic acid is an antioxidant that acts as a scavenger for a wide range of reactive oxygen species (ROS). Both tumour metastasis and cell migration have been correlated with the intracellular ROS level, so it was postulated that the inhibitory effect of ascorbic acid derivatives on cell motility may be caused by scavenging of ROS. Time-lapse analyses of Walker 256 carcinosarcoma cell migration showed that both the speed of movement and the cell displacement were inhibited by ascorbic acid applied in concentrations ranging from 10 to 250 μM. This effect correlated with a reduction in the intracellular ROS level in WC 256 cells, suggesting that ROS scavenging may be a mechanism responsible for the inhibition of WC 256 cell migration. However, another potent antioxidant, N-acetyl-L-cysteine, also efficiently decreased the intracellular ROS level in WC 256 cells, but did not affect the migration of the investigated cells. These results demonstrate that intact, unmodified ascorbic acid applied in physiologically relevant and nontoxicconcentrations exerts an inhibitory effect on the migration of WC 256 carcinosarcoma cells, and that this may be one of the factors responsible for the anti-metastatic activity of vitamin C. However, our data does not support the hypothesis that the scavenging of intracellular ROS is the main mechanism in the inhibition of cancer cell migration by ascorbic acid.

5

Non-specific inflammatory bowel diseases and the risk of tumour growth

75%

Dudzinska E., Gryzinska M., Ognik K., Krauze M., Listos P.

Medycyna Weterynaryjna

|

2018

|

tom 74

|

nr 04

Inflammatory bowel disease (IBD), which includes mainly ulcerative colitis (UC) and Crohn’s disease (Lesniowski-Crohn’s, ChL-C, CD), is a chronic and recurrent inflammatory condition of the gastrointestinal tract with multifactorial causes. Both types of IBD are characterized by chronic inflammation with periods of remission and exacerbation. An increasing number of studies have recently shown that chronic inflammation plays an important role in the carcinogenesis of colorectal cancer (CRC), generating suitable microenvironments for the formation and progression of the disease. The main factors are chronic inflammation as well as the scope and duration of the disease. The pro-inflammatory interleukins IL-13, IL-8 and TNF-α play an important role in tumorigenesis. It is further emphasized that reactive oxygen species (ROS) and reactive nitrogen species produced by inflammatory cells may interact with key genes involved in carcinogenic pathways, such as TP53. Carcinogenesis in IBD involves proteins determined by the genes DLG5, OCTN and NOD2. Immunosuppressive drugs, such as thiopurines and methotrexate, may play a role in extra-intestinal tumour development by impairing the immune system and surveillance of tumour cells or by inducing DNA damage. Recognition of neoplastic changes associated with IBD is difficult due to the heterogeneity of the endoscopic image and variation in the diagnosis depending on the observer. Therefore surveillance of IBD patients by a multidisciplinary team is essential for early detection of the neoplastic process.

6

Antibody-based antiangiogenic and antilymphangiogenic therapies to prevent tumor growth and progression

75%

Bzowska M., Mezyk-Kopec R., Prochnicki T., Kulesza M., Klaus T., Bereta J.

Acta Biochimica Polonica

|

2013

|

tom 60

|

nr 3

Blood and lymphatic vessel formation is an indispensable factor for cancer progression and metastasis. Therefore, various strategies designed to block angiogenesis and lymphangiogenesis are being investigated in the hope to arrest and reverse tumor development. Monoclonal antibodies, owing to their unequalled diversity and specificity, might be applied to selectively inhibit the pathways that cancer cells utilize to build up a network of blood vessels and lymphatics. Among the possible targets of antibody-based therapies are proangiogenic and prolymphangiogenic growth factors from the VEGF family and the receptors to which they bind (VEGFRs). Here, we present molecular mechanisms of angiogenesis and lymphangiogenesis exploited by tumors to progress and metastasise, with examples of antibody-based therapeutic agents directed at interfering with these processes. The expanding knowledge of vascular biology helps to explain some of the problems encountered in such therapies, that arise due to the redundancy in signaling networks controlling the formation of blood and lymphatic vessels, and lead to tumor drug resistance. Nonetheless, combined treatments and treatments focused on newly discovered proangiogenic and prolymphangiogenic factors give hope that more prominent therapeutic effects might be achieved in the future.

7

Evidence for an immunoregulatory role of OX2 with its counter ligand [OX2L] in the regulation of transplant rejection, fetal loss, autoimmunity and tumor growth

75%

Gorczynski R. M.

Archivum Immunologiae et Therapiae Experimentalis

|

2001

|

tom 49

|

nr 4

8

Inhibitory effect of acetylsalicylic acid on metalloproteinases activity in human lung adenocarcinoma at different stages of differentiation

75%

Karna E., Palka J.

Folia Histochemica et Cytobiologica. Supplement

|

2001

|

tom 39

|

nr 1

9

Spontaneous apoptosis of melanotic and amelanotic melanoma cells in different phases of cell cycle: relation to tumor growth

75%

Cichorek M., Kozlowska K., Wachulska M., Zielinska K.

Folia Histochemica et Cytobiologica

|

2006

|

tom 44

|

nr 1

10

Preparation and characterization of cytotoxic immunoliposomes for the simultaneous inhibition of angiogenesis and tumor growth

75%

Schwendener R. A.

Cellular and Molecular Biology Letters

|

1999

|

tom 04

|

nr 2

11

Intensive tumor suppression by anti-angiogenic photodynamic therapy with polycation-modified liposomal photosensitizer

75%

Takeuchi Y., Kurohane K., Nango N., Oku N.

Cellular and Molecular Biology Letters

|

2002

|

tom 07

|

nr 2

12

Synthesis and characterization of Au[III] coordinated complexes with oxamic acid derivatives

63%

Negreanu-Pirjol T., Zagan S.

Journal of Elementology

|

2005

|

tom 10

|

nr 4 Suppl.1

75

13

Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik

Nutraceuticals as anti-angiogenic agents: hopes and reality

63%

Dulak J.

Journal of Physiology and Pharmacology. Supplement

|

2005

|

tom 56

|

nr 1

51-69

Angiogenesis, the formation of new blood vessels from preexisting vascular network is a driving force of organ development in ontogeny, is necessary for ovulation and hair growth, and is prerequisite for proper wound healing. It is also a critical mechanism of numerous diseases, the most important of which are cancer and atherosclerosis. Therefore, modulation of angiogenesis is considered as therapeutic strategies of great importance for human health. Numerous bioactive plant compounds, often referred to as nutraceuticals are recently tested for the potential clinical applications. Among the most frequently studied are resveratrol, a polyphenol present in red-wine and grape-seed, epigallocatechin-3- gallate (EGCG) from green tea and curcumin from Curcuma longa. It is also possible that components of other plants, including the constituents of local food diet may find application for modulation of angiogenesis, provided that their effectiveness will be confirmed in controlled, scientifically validated trials.

14

Relationship between magnesium status and the growth and metastasis of experimental mouse tumours

63%

Nasulewicz A., Wietrzyk J., Wolf F. I., Dzimira S., Madej J., Maier J. A. M., Rayssiguier Y., Mazur A., Opolski A.

Journal of Elementology

|

2005

|

tom 10

|

nr 4 Suppl.1

73-74

15

Two Gln187 mutants of human soluble APRIL inhibit proliferation of lung carcinoma A549 cells

63%

Dai S., Zheng Y., Chen B., Gao M., Zhang Y., Zhang L., Gong W., He F.

Acta Biochimica Polonica

|

2009

|

tom 56

|

nr 4

703-710

Soluble APRIL (sAPRIL), the active form of a proliferation-inducing ligand (APRIL), is implicated in the proliferation of tumor cells. Suppressing APRIL function has been considered as a potential strategy for the therapy of APRIL-associated tumors. In the present study, we generated human sAPRIL and its two mutants, Gln187-D-sAPRIL (Gln187 deleted) and Gly187-sAPRIL (Gln187 replaced by Gly). In vitro experiments showed that the two mutants had similar specific binding capacity to lung carcinoma A549 cells compared to the wild-type sAPRIL, and both, especially Gly187-sAPRIL, exhibited significant antagonistic effect on sAPRIL-induced tumor cell proliferation in a dose-dependent manner, which might be predominantly mediated by blocking sAPRIL-induced MEK and ERK phosphorylation but not p38MAPK or JNK signaling. In vivo experiments with nude mice bearing A549 cell-derived xenograft tumor showed that only the Gly187-sAPRIL mutant could significantly suppress the tumor growth. These results suggest that Gln187 may be a crucial amino acid in APRIL-mediated tumor cell proliferation via the MEK-ERK signaling pathway and that the sAPRIL mutants may serve as novel potential antagonists of APRIL for the therapy of APRIL-associated cancers.

16

Microvessel density assessment in benign and malignant endometrial changes

63%

Czekierdowski A., Czekierdowska S., Czuba B., Cnota W., Sodowski K., Kotarski J., Zwirska-Korczala K.

Journal of Physiology and Pharmacology. Supplement

|

2008

|

tom 59

|

nr 4

45-51

17

Pericytes and microvessel density assessment in women with ovarian malignant tumors

63%

Czekierdowska S., Rolinski J., Czekierdowski A., Bednarek W., Kotarski J.

Polish Journal of Environmental Studies

|

2004

|

tom 13

|

nr Suppl.2, Part 1

Objective: The aim of this study was to assess ovarian cancer angiogenesis by comparing intratumoral microvessel density (MVD) with pericytes expression. Methods: Tumor specimens from 34 women operated because of malignant adnexal tumors were evaluated. Pericytes were assessed with anti-desmin antibody and microvessels were counted following CD-34 antigen detection. Histological type, grading, FIGO stage and menopausal status were compared with MVD and pericytes expression. Results: The means of MVD in serous and mucinous tumors were 25 (range: 8-83) and 22 (range: 8-50), respectively. The difference between medians of MVD and mean number of pericytes per high power field were not statistically significant. Also, there was no correlation between assessed markers and differentiation grade and FIGO stage and tumor type. Conclusion: MVD counting with CD-34 antigen, but not desmin expression for pericytes detection seems to be a useful parameter for neoangiogenesis assessment in ovarian cancers.

18

Combination of vasostatin and cyclophosphamide in the therapy of murine melanoma tumors

63%

Jazowiecka-Rakus J., Jarosz M., Kozlowska D., Sochanik A., Szala S.

Acta Biochimica Polonica

|

2007

|

tom 54

|

nr 1

Growth of tumors is strongly dependent upon supply of nutrients and oxygen by de novo formed blood vessels. Inhibiting angiogenesis suppresses growth of primary tumors as well and affects development of metastases. We demonstrate that recombinant MBP/vasostatin fusion protein inhibits proliferation of endothelial cells in vitro. The therapeutic usefulness of such intratumorally delivered recombinant protein was then assessed by investigating its ability to inhibit growth of experimental murine melanomas. In the model of B16-F10 melanoma the MBP/vasostatin construct significantly delayed tumor growth and prolonged survival of treated mice. A combination therapy involving MBP/vasostatin construct and cyclophosphamide was even more effective and led to further inhibition of the tumor growth and extended survival. We show that such combination might be useful in the clinical setting, especially to treat tumors which have already formed microvessel networks.

19

Cytokine regulation of monocyte recruitment

63%

Mantovani A., Bottazzi B., Sozzani S., Peri G., Allavena P., Dong Q. G., Vecchi A., Colotta F.

Archivum Immunologiae et Therapiae Experimentalis

|

1995

|

tom 43

|

nr 2

20

Retroviral targeting of proliferating endothelial cells

63%

Gornikiewicz A., Zommer A., Jakesz R., Gnant M., Brostjan C.

Acta Biochimica Polonica

|

2005

|

tom 52

|

nr 3

Tumor growth requires the formation of new blood vessels by endothelial cells. Thus, surface molecules - such as angiogenin receptors - that are selectively expressed on growing endothelium represent an attractive target for directed delivery of compounds to tumor tissue. We attempted to obtain genetically engineered retroviral vectors targeted to the endothelium by inserting the human angiogenin sequence into Moloney murine leukemia virus envelope glycoprotein. Abundant expression of the chimeric protein could be verified. However, while being selective for proliferating human endothelial cells, the recombinant retroviral particles displayed low transduction efficiencies and thus have to be further improved.

Ograniczanie wyników

Insights into the mechanisms involved in mediating magnesium regulation of tumor growth

Advances in studies on invasive tumor growth and metastasis

Alterations in glycosaminoglycan composition of methylcholanthrene - induced sarcoma at various stages of the tumour growth

Ascorbic acid inhibits the migration of Walker 256 carcinosarcoma cells

Non-specific inflammatory bowel diseases and the risk of tumour growth

Antibody-based antiangiogenic and antilymphangiogenic therapies to prevent tumor growth and progression

Evidence for an immunoregulatory role of OX2 with its counter ligand [OX2L] in the regulation of transplant rejection, fetal loss, autoimmunity and tumor growth

Inhibitory effect of acetylsalicylic acid on metalloproteinases activity in human lung adenocarcinoma at different stages of differentiation

Spontaneous apoptosis of melanotic and amelanotic melanoma cells in different phases of cell cycle: relation to tumor growth

Preparation and characterization of cytotoxic immunoliposomes for the simultaneous inhibition of angiogenesis and tumor growth

Intensive tumor suppression by anti-angiogenic photodynamic therapy with polycation-modified liposomal photosensitizer

Synthesis and characterization of Au[III] coordinated complexes with oxamic acid derivatives

Nutraceuticals as anti-angiogenic agents: hopes and reality

Relationship between magnesium status and the growth and metastasis of experimental mouse tumours

Two Gln187 mutants of human soluble APRIL inhibit proliferation of lung carcinoma A549 cells

Microvessel density assessment in benign and malignant endometrial changes

Pericytes and microvessel density assessment in women with ovarian malignant tumors

Combination of vasostatin and cyclophosphamide in the therapy of murine melanoma tumors